Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controlling Myopia: Insights from a Nation-Wide Clinical Practice Survey.

Journal of clinical medicine·2026
Same author

Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Rethinking prognosis in multiple sclerosis: a multiaxial perspective.

Nature reviews. Neurology·2026
Same author

Motor, Extrapyramidal, and Cognitive Involvement in RFC1 Disease: A Systematic Review and Meta-Analysis.

Neurology. Genetics·2026
Same author

Pediatric sensorimotor cortical responsiveness to intracerebral stimulation during stereoelectroencephalographic monitoring: Age effects and area specificity.

Epilepsia·2026
Same author

Structure-Function Decoupling of the Sensorimotor and Default Mode Networks in Black Americans With MS.

Annals of clinical and translational neurology·2026
Same journal

Characterizing Onset Limit and Surgical Outcome Factors in Type II Focal Cortical Dysplasia-Related Epilepsy.

Neurology. Clinical practice·2026
Same journal

Efficacy and Safety of Perampanel in Patients With Brain Tumor-Related Epilepsy: A Systematic Review and Meta-Analysis.

Neurology. Clinical practice·2026
Same journal

Patient-Reported Symptom Burden in Individuals With Parkinson Disease.

Neurology. Clinical practice·2026
Same journal

Global Access to Diagnostic Paraclinical Testing Incorporated in the 2024 Revised McDonald Criteria: Disparities and Opportunity.

Neurology. Clinical practice·2026
Same journal

Clinical Differentiation of Self-Limited Epilepsy With Autonomic Seizures (Panayiotopoulos Syndrome) and Childhood Migraine.

Neurology. Clinical practice·2026
Same journal

The National Association of Epilepsy Centers Accreditation Criteria Should Include Care for People With Functional/Dissociative Seizures.

Neurology. Clinical practice·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Alessio Signori1,2, Noemi Montobbio1, Francesca Bovis1

  • 1Department of Health Sciences, University of Genoa, Italy; and.

Neurology. Clinical Practice
|May 11, 2026
PubMed
Summary
This summary is machine-generated.

Tolebrutinib uniquely improved disability in relapsing multiple sclerosis (MS) without reducing relapses, unlike other disease-modifying therapies (DMTs). This dissociation suggests a novel mechanism of action for tolebrutinib in MS management.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Experiment Videos

Last Updated: May 13, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Relapsing multiple sclerosis (MS) is characterized by relapses and progressive disability.
  • Disease-modifying therapies (DMTs) aim to reduce both relapse frequency and disability worsening.
  • Understanding the relationship between relapse prevention and disability reduction is crucial for evaluating DMT efficacy.

Purpose of the Study:

  • To compare the effects of tolebrutinib on confirmed disability worsening (CDW) versus relapse prevention against other DMTs in relapsing MS.
  • To determine if tolebrutinib's treatment effects on CDW diverge from its effects on relapse prevention.

Main Methods:

  • A meta-analysis of phase 3 trials comparing DMTs (ofatumumab, ponesimod, ublituximab, evobrutinib, tolebrutinib) against teriflunomide was conducted.
  • Effect estimates for annualized relapse rate (ARR) and CDW (at 24 weeks) were extracted and analyzed.
  • Weighted linear regression assessed the association between treatment effects on CDW and ARR, with tolebrutinib analyzed separately.

Main Results:

  • A strong linear association (R² = 0.997) was found between ARR reduction and CDW improvement for four DMTs, indicating proportional benefits.
  • Tolebrutinib demonstrated a significant reduction in CDW (HR 0.71) but showed no significant effect on ARR (RR 1.03).
  • This represents a dissociation between disability and relapse outcomes for tolebrutinib compared to other DMTs.

Conclusions:

  • Tolebrutinib is the first DMT observed to improve disability without a measurable impact on relapse rates in relapsing MS.
  • This dissociation suggests a potential distinct mechanism of action for tolebrutinib in managing MS progression.
  • Further research is warranted to elucidate the specific pathways through which tolebrutinib exerts its disability-sparing effects.